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ABSTRACT: Introduction: Amyotrophic lateral sclerosis (ALS) and
frontotemporal lobar degeneration (FTLD) are considered part of
the same pathological spectrum. There is an increased risk of ALS
in patients who have had melanoma. The risk of FTLD in mela-
noma (or cancer) patients is unknown. We aimed to study if
C9ORF72 expansion is linked to a higher prevalence of mela-
noma. Methods: We selected patients with a diagnosis in the
ALS-FTLD spectrum who were tested for pathogenic mutations.
Medical history was reviewed, to identify those with pathologically
documented melanomas. Results: We included 189 patients.
Sixty-two had identified pathogenic mutations (39 C9ORF72).
C9ORF72 carriers had a significantly higher risk of melanoma
(odds ratio = 24.709; P < 0.007). There was no association with
phenotype. Conclusions: These findings suggest that patients
with a history of melanoma may have an increased probability of
carrying a C9ORF72 repeat expansion. ALS or FTLD carriers of
C9ORF72 should undergo surveillance for skin changes.
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Several studies have examined the risk of cancer in
neurodegenerative diseases, including Parkinson and
Alzheimer diseases, which have been reported to have
a protective effect against the overall development of
cancer.1–5 The same overall protective effect has been
reported recently in amyotrophic lateral sclerosis
(ALS),6 but some types of cancer seem to have
increased prevalence in this population. There is
mounting evidence of an increased risk of ALS in
patients who have had melanoma.7,8 ALS and fronto-
temporal lobar degeneration (FTLD) are considered
part of the same pathological spectrum and share
common pathogenic genetic mutations, with the chro-
mosome 9 open reading frame 72 (C9ORF72) expan-
sion being the most common in both.9 A small study
in FTLD reports overall lower risk of cancer.10
Several genes have been implicated in the association
between cancer and neurodegenerative diseases,
including progranulin (GRN),11 fused-in-sarcoma
(FUS),12 and SQSTM1.13 However, we still lack the
understanding of the underlying mechanism that would
explain such association.14 Exploring the relationship
between cancer and neurodegenerative diseases could
provide new clues relevant to the etiologies and poten-
tial therapies for both sets of conditions.
Of interest, analysis of skin biopsies ofC9ORF72 repeat
expansion ALS patients revealed early TDP-43 deposi-
tion and abnormal extracellular matrix findings,15 sug-
gesting a possible link between this expansion and skin
disease.
We aimed to study the hypothesis that C9ORF72
expansion is linked to a higher prevalence ofmelanoma.
PATIENTS AND METHODS
Patients. We selected ALS-FTLD spectrum patients, fol-
lowed at the dementia and neuromuscular clinics of our
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department with the most recent appointment between
2010 and 2017, who were tested for pathogenic mutations in
superoxide dismutase (SOD), TANK-binding kinase 1 (TBK1),
GRN, microtubule-associated protein tau (MAPT), valosin-
containing protein (VCP), FUS, charged multivesicular body
protein 2B (CHMP2B), or C9ORF72 repeat expansions.
This study was approved by our hospital ethical committee,
and all patients or their close relatives gave consent for data
collection.
Methods. We reviewed all subjects’ medical history to iden-
tify those with histopathologically documented melanoma dur-
ing their lifetime. This was done with the families (and the
patients whenever they could give reliable information) and
by reviewing all the patients’ medical records.
To investigate a possible link between c90rf72 repeat
expansion and melanoma, we compared the risk of melanoma
between C9ORF72 repeat expansion carriers and all patients
who tested negative for C9ORF72 expansion. We further com-
pared the risk of melanoma between C9ORF72 carriers and
patients with other identified pathogenic mutations.
We also compared melanoma prevalence across different
phenotypes and basal cell carcinoma prevalence between
C9ORF72 carriers and noncarriers.
Statistical Analysis. Statistical analysis was performed using
SPSS statistical software (version 20.0; SPSS Inc., Chicago, IL).
Categorical data are presented as frequency (percentage) and
were compared using χ2-test. Continuous variables were com-
pared using Student’s t-test. To estimate the association
between carrying a C9ORF72 expansion and developing mela-
noma, a logistic regression was performed to calculate the odds
ratio, adjusted for age. A Bejamini-Hochberg post hoc correction
for multiple comparisons was performed, giving a α = 0.0083).
RESULTS
We included 189 patients. Of those, 157 patients had
a primary FTLD diagnosis and 32 an ALS diagnosis. Of
the total, 62 had identified pathogenic mutations:
39 subjects had C9ORF72 repeat expansions, 3 had
MAPT mutations, and 20 had GRN mutations. Patient
diagnosis and mutation status are provided in Table 1.
The mean age of all subjects was of 63.8 (10.5)
years. Mutation carriers were significantly younger
(59.3  10.4 years; P < 0.001), as were the C9ORF72
expansion carriers (60.6  10.7 years old; P = 0.031).
54.5% of the population was male, and there were
no gender differences between groups.
Seven patients had a diagnosis of melanoma; 6 of
them were carriers of a C9ORF72 repeat expansion,
and the other had no identified mutation. Three addi-
tional patients had basal cell carcinoma: 2 of them were
C9ORF72 expansion carriers and 1 had no identified
pathogenicmutation. All the 6 patients with a C9ORF72
expansion and melanoma (15.4% of the C9ORF72 car-
riers) belonged to 4 unrelated families. Five of them
had ALS and one had FTLD. Three of them were from
the same family (7 members carrying the mutation and
manifesting disease, 3 of whom had melanoma). The
patient with melanoma without a pathogenic mutation
was unrelated to any of the patients withmelanoma.
As depicted in FIGURE 1, C9ORF72 carriers had a
significantly higher prevalence of melanoma
(P < 0.001), comparing with all the other patients with
a negative test for this expansion (odds ratio = 24.709;
95% confidence interval, 2.440–249.804; P < 0.007;
Nagelkerke R square of 0.259; χ2 = 10.637). Com-
pared only with other mutation carriers, melanoma
prevalence was still significantly higher (P = 0.048).
There was association with neither FTLD nor ALS
(P = 0.216) in C9ORF72 carriers.
Other melanoma-causing mutations were excluded
in the two living C9ORF72 carriers with history of mel-
anoma. CDKN2A was tested in the 2 patients with mel-
anoma and C9ORF72 repeat expansions and were
negative. One of the patients was further studied for
CDK4, MC1R, CDKN2B, and GNAQ and was negative
for pathogenic mutations in those genes.
DISCUSSION
Our study suggests a link between C9ORF72 repeat
expansions and increased risk of melanoma. Addition-
ally, melanoma’s prevalence in C9ORF72 carriers is
higher than that of basal cell carcinoma, which is the
inverse of the general population.16 Several previous
studies analyzing the risk of ALS in cancer patients
revealed a link between both conditions. None of these
studies analyzed the role of specific mutations in this
association. We speculate that the increased risk of
melanoma found in those studies can be (at least par-
tially) due to the existence of occult C9ORF72 repeat
expansion carriers on those samples. It could also be
that a common pathway is involved in the ALS/FTLD
spectrum and melanoma development, in which
C9ORF72 repeat expansions may play a role.
It has been shown that TDP-43 nuclear overexpres-
sion with no cytoplasmic inclusions can be detected in
skin biopsies from ALS patients.15 In addition, analysis
of cultured fibroblasts and keratinocytes from skin
biopsies of C9ORF72 repeat expansion ALS patients
reveals abnormal extracellular matrix findings, such as
epidermal undifferentiation, abnormal dermo-
epidermal junction, delamination keratinocyte infiltra-
tion, and collagen disorganization.17 Consistently, an in
silico bioinformatics data mining analysis of the molecu-
lar network of C9ORF72 showed a down-regulation of
collagen-related genes as well as genes implicated in
the assembly, synthesis, and cross-linking of collagen
Table 1. Diagnosis and mutation status for all patients (white
squares) and only patients with melanoma (black-filled squares).
ALS FTLD Total Melanoma
C9ORF72 14 25 39 6
PGRN 0 20 20 0
MAPT 0 3 3 0
No mutation 18 109 127 1
Total 32 157 189 7
Melanoma 5 2 7
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fibrils.18 These findings suggest that cytoskeletal
dynamics and/or remodeling of extracellular matrix
disturbances might be key factors of the disease and
associate C9ORF72 repeat expansions with those
changes, possibly increasing the risk for melanoma.
One possible bias would be genetic linkage of the
C9ORF72 repeat expansion to a mutation in a nearby
gene involved in melanoma development. Several gene
mutations have been associated withmelanoma, namely
CDK4, CDKN2A, GNAQ, RB1, PPP6C, RAC1, SNX31,
TACC1, STK19, ARID2, BRAF, NRAS, HRAS, TERT, KIT,
TP53, EGFR, ERBB4, PIK3CA, PDGFRA.19 Some of these
(CDKN2A and GNAQ) localize in the short arm of the
chromosome 9. CDKN2A was tested in the 2 patients
with melanoma and C9ORF72 repeat expansions and
was negative. One of the patients was further studied for
CDK4, MC1R, CDKN2B, and GNAQ somatic mutations
and was negative for pathogenic mutations in those
genes. A phenomenon of epistasis between C9ORF72
and CDKN2A or GNAQ is also possible, given their rela-
tive proximity, and should be further addressed.
The major limitation of this work is the low number
of melanomas, with half of them coming from the same
family. There may be an underlying mutation or envi-
ronmental risk factor that we did not identify. However,
even if we exclude those patients, the difference would
still be significantly higher (P = 0.002). Also, there was a
statistically significant difference in the ages of the
groups. This was expected given the lower age of onset
of patients with pathogenic mutations. However, this dif-
ference is only 3 years, and if affecting the prevalence of
melanoma, would only potentially increase the differ-
ence, as they had less time to develop melanoma.
These findings suggest that ALS or FTLD patients
with a personal history of melanoma may be at
increased risk of carrying a C9ORF72 repeat expan-
sion, and that genetic testing for C9ORF72 might be
considered in those patients. Carriers of C9ORF72
should undergo surveillance for skin changes.
Ethical Publication Statement: We confirm that we have read the
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ABSTRACT: Introduction: Valosin-containing protein (VCP)
variants that affect muscle, bone, and the nervous system are
termed multisystem proteinopathy. VCP myopathy is manifested
as limb-girdle weakness, distal weakness and scapuloperoneal
weakness. Methods: We reviewed clinical, genetic, and muscle
biopsy data from 6 members of a family with VCP myopathy.
Results: Clinical features of family members were complex and
included dementia, myopathy, and hearing impairment. Ophthal-
moplegia, ptosis, and dysphagia were present in 3 siblings.
Rimmed vacuoles were observed in muscle biopsies, consistent
with the pathological changes of VCP myopathy. A heterozygous
VCP c.463C>A (p.R155S) that segregated in an autosomal-
dominant pattern was identified by genetic analysis. Conclusions:
VCP myopathy can cause unusual manifestations that include
ophthalmoplegia, ptosis, and dysphagia. This study increased our
understanding of the clinical manifestations of VCP myopathy.
Muscle Nerve 59:365–369, 2019
The gene valosin-containing protein (VCP) encodes
the VCP protein comprising of 806 amino acids,
located at 9p13.3. VCP is a member of the ATPases
associated with various cellular activities (AAA+)
superfamily1 and consists of an N-terminal domain,
ATP enzyme domains (D1, D2), C-terminal domain
and intermediate junction regions.2 VCP is a
ubiquitously-expressed hexameric protein involved
in various ubiquitin-dependent cellular processes
and several essential cell protein pathways including
cell membrane fusion, cell cycle, postmitotic Golgi
reassembly, nuclear envelope reconstruction, sup-
pression of apoptosis, DNA damage response, and
the ubiquitin–proteasome degradation pathway.3–5
VCP disease is a rare, autosomal dominant (AD) dis-
order first reported in 19826 that may present with
varying combinations of inclusion body myopathy
(IBM), Paget disease of bone (PDB), and fronto-
temporal dementia (FTD) (OMIM#167320), or may
manifest as amyotrophic lateral sclerosis, Parkinson’s
disease, cardiomyopathy, Charcot-Marie-Tooth dis-
ease, or hereditary spastic paraparesis.7
The most common clinical presentation of VCP
disease is myopathy, seen in almost 90% of cases and
characterized by late adult-onset shoulder and pelvic
girdle weakness as well as distal myopathy. Facial
muscles are occasionally involved. The serum crea-
tine kinase (CK) is normal or slightly elevated. The
most common findings of muscle biopsy are rimmed
vacuoles and ubiquitin-, TDP-43-, and VCP-positive
inclusions.8 PDB is seen in approximately 50% of
patients, characterized by abnormal bone homeosta-
sis resulting in polyostotic skeletal disorganization,
pathological fractures, or osteolytic bone lesions,
high alkaline phosphatase (ALP) and radiographic
changes. FTD is recognized in one third of patients,
presenting with early behavioral or language
changes. Here, we report on a family of 6 VCP
patients with a heterozygous missense mutation VCP
c.463C>A (p.R155S) whose main clinical manifesta-
tion was myopathy with some unusual features.
MATERIALS AND METHODS
This study was approved by the Ethics Committee of the
Third Hospital of Hebei University. Written informed con-
sent was obtained from all patients and/or their legal guard-
ians. Three siblings were clinically assessed, and their
medical records including serum CK and ALP levels; radio-
graphs of the pelvis, skull, and spine; lower limb muscle
brain MRI; and needle electromyography (EMG) and nerve
conduction studies (NCS) were reviewed. Information about
the other patients was obtained from a description given by
their guardians. Blood samples were collected from 9 family
members.
Open muscle biopsy was performed on the tibialis anterior of
the 3 siblings under local anesthesia. The specimens were stained
with routine stains using standard techniques. In addition, ultra-
structural examination was performed on the proband.
The target gene (1 patient)/whole-exome (4 patients) cap-
ture experiment was conducted following the manufacturer’s
protocol (My Genostics, Beijing, China).9 Confirmation of the
findings of next generation sequencing (NGS) and segregation
Additional supporting information may be found in the online version of
this article.
Abbreviations: AD, autosomal dominant; ALP, alkaline phosphatase;
CMAP, compound muscle action potentials; CK, creatine kinases; EMG,
electromyography; FTD, frontotemporal dementia; IBM, inclusion body
myopathy; MRC, Medical Research Council; MoCA, Montreal Cognitive
Assessment; NCS, nerve conduction studies; NGS, next generation
sequencing; OPDM, oculopharyngodistal myopathy; PDB, Paget disease
of bone; VCP, valosin-containing protein
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